---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-015621"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2023-09-11T23:59:59+00:00"
generated_at: "2026-06-10T21:47:52.275921+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "low"
source: SEC EDGAR
---

# Aprea Therapeutics updates corporate presentation for Sep 2023; details not disclosed in excerpt

## Summary
- Filing consists solely of an updated corporate slide deck dated September 2023.
- Presentation title indicates focus on precision oncology and synthetic lethality.
- No financial results, guidance, leadership changes, or deal announcements in the filing.
- Exhibit excerpt does not contain specific trial data or operational milestones.

## SEC filing metadata
- accession: 0001558370-23-015621
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2023-09-11T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000155837023015621/0001558370-23-015621-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000155837023015621/apre-20230911x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-015621
- JSON: https://secwatch.observer/filing/0001558370-23-015621.json
- Plain text: https://secwatch.observer/filing/0001558370-23-015621.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.